Recombinant Humanized (from mouse) antibody to Human ERBB2. Trastuzumab emtansine (ado-trastuzumab emtansine, trade name trastuzumab emtansine) is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (trastuzumab) linked to the cytotoxic agent mertansine (DM1). Trastuzumab alone stops growth of cancer cells by binding to the HER2/neu receptor, whereas mertansine enters cells and destroys them by binding to tubulin. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the toxin specifically to tumor cells. The conjugate is abbreviated T-DM1.
Figure 1 Binding, internalization, and externalization of trastuzumab emtansine (T-DM1) are not significantly different between N87 and N8716-8 cells.
Human epidermal growth factor receptor 2 (HER2) expression in N87 and N87-16-8 cells was analyzed by Western blotting.
Figure 2 Binding, internalization, and externalization of trastuzumab emtansine (T-DM1) are not significantly different between N87 and N8716-8 cells.
N87 and N87-16-8 cells were treated with 1 ug/mL DyLight 488 NHS Ester-labeled T-DM1 on ice for 1 h and washed three times with cold FACS buffer, after which binding of T-DM1 to cells was analyzed by flow cytometry.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.